한글목차

세계 위암 치료 시장은 2024년 39억 8,000만 달러로 평가되며, 2030년에는 57억 달러에 달할 것으로 예상되며, 연평균 6.12%의 성장률을 보일 것으로 예상됩니다.

위암은 위 점막에 발생하는 악성 종양으로, 치료에는 수술, 화학요법, 방사선요법, 표적 치료제, 면역요법, 병용요법 등 다각적인 접근이 필요합니다. 시장 성장은 특히 동아시아 및 라틴아메리카 등의 지역에서 전 세계 위암 발병률의 증가, 진단 기술 및 치료 혁신의 발전이 주요 요인으로 작용하고 있습니다. 위암에 대한 인식 개선과 조기 발견을 위한 노력이 임상 결과 개선에 기여하고 있습니다. 정밀의료와 바이오마커 기반 치료법 개발도 치료의 전망을 재구성하고 있습니다. 이러한 발전에도 불구하고, 시장은 치료비 상승, 치료 저항성, 일부 지역에서는 첨단 의료에 대한 접근성 제한 등의 도전에 직면해 있습니다. 그럼에도 불구하고, 지속적인 연구, 제약사 간 제휴, 환자 중심의 치료 전략은 보다 개인화되고 효과적인 치료 솔루션을 향한 시장 성장을 촉진하고 있습니다.

시장 촉진요인

위암 발병률 증가

주요 시장 과제

진행 단계에 대한 제한된 치료 옵션

주요 시장 동향

면역요법의 장점

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 위암 치료 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율과 예측
  • 치료 종류별(화학요법, 표적요법, 면역요법, 방사선 치료, 수술)
  • 최종사용자별(외래 수술 센터, 병원 및 전문 클리닉, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 위암 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 위암 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 독일
  • 영국
  • 이탈리아
  • 프랑스
  • 스페인

제8장 아시아태평양의 위암 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 남미의 위암 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 위암 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 인수합병

제13장 PESTEL 분석

제14장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 능력
• 고객의 능력
• 대체품의 위협

제15장 세계의 위암 치료 시장 : SWOT 분석

제16장 경쟁 구도

• Abbott Laboratories Inc.
• Amgen, Inc.
• Celltrion Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Agilent Technologies Inc.
• AstraZeneca Plc
• Pfizer Inc.
• Eli Lilly & Co.
• GlaxoSmithKline Plc.

제17장 전략적 제안

제18장 조사 회사 소개 및 면책사항

영문목차

The Global Gastric Cancer Therapy Market was valued at USD 3.98 billion in 2024 and is projected to reach USD 5.70 billion by 2030, growing at a CAGR of 6.12%. Gastric cancer, a malignancy originating in the stomach lining, requires a multifaceted approach to treatment that includes surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy, and combination treatments. Market growth is primarily fueled by the rising global incidence of gastric cancer, particularly in regions such as East Asia and Latin America, as well as advancements in diagnostic techniques and therapeutic innovations. Increasing awareness and early detection initiatives have contributed to better clinical outcomes. Precision medicine and the development of biomarker-based therapies are also reshaping the treatment landscape. Despite these advancements, the market faces challenges such as high treatment costs, resistance to therapy, and limited access to cutting-edge care in certain regions. Nonetheless, continuous research, partnerships among pharmaceutical players, and patient-centered care strategies are propelling the market toward more personalized and effective therapeutic solutions.

Key Market Drivers

Rising Incidence of Gastric Cancer

The increasing incidence of gastric cancer is a critical driver of the Global Gastric Cancer Therapy Market. In 2020, over 1.1 million new gastric cancer cases were reported globally, with approximately 770,000 related deaths. The disease is notably more prevalent in males, and Eastern Asia continues to report the highest incidence. Aging populations, lifestyle factors such as smoking and dietary habits, and environmental exposures contribute to the disease's global rise. Regions like Japan, China, South Korea, and parts of Latin America and Europe exhibit particularly high prevalence. In India, for example, northeastern districts like Aizawl and Papumpare have recorded alarmingly high age-adjusted rates. As early detection improves and more cases are diagnosed, the demand for effective treatment options has intensified. This trend is driving the expansion of chemotherapy, immunotherapy, and targeted therapy offerings to meet the growing therapeutic needs of patients worldwide.

Key Market Challenges

Limited Treatment Options for Advanced Stages

Advanced-stage gastric cancer presents a major treatment challenge, largely due to its aggressive progression and resistance to conventional therapies. Once the cancer has metastasized, standard treatments such as chemotherapy, targeted therapies, and immunotherapy may lose efficacy due to genetic mutations and immune evasion mechanisms developed by cancer cells. As a result, treatment outcomes in advanced stages remain limited. Research is increasingly focusing on combination therapies and novel targets to overcome resistance and improve survival rates. Clinical trials are critical in evaluating these innovations and expanding the therapeutic arsenal. However, access to these new treatments is often limited by geographic, economic, and regulatory constraints. Overcoming these hurdles will require coordinated efforts among research institutions, pharmaceutical companies, and regulatory bodies to broaden treatment options and ensure equitable access for patients battling advanced gastric cancer.

Key Market Trends

Immunotherapies Dominance

Immunotherapy is emerging as a dominant force in the Global Gastric Cancer Therapy Market, revolutionizing the traditional treatment approach by leveraging the immune system to fight cancer. Immune checkpoint inhibitors-such as those targeting PD-1, PD-L1, and CTLA-4-have demonstrated remarkable success in treating patients with advanced gastric cancer. These therapies have led to longer survival and improved quality of life for some patients who previously had limited treatment options. Their ability to generate durable immune responses has opened up new possibilities, especially when used in combination with chemotherapy or targeted therapy. However, response rates vary, and immune-related adverse events remain a concern. Ongoing research is focused on identifying biomarkers to better predict patient response, optimizing treatment combinations, and reducing side effects. As clinical evidence grows and regulatory approvals expand, immunotherapies are expected to remain central to the evolving landscape of gastric cancer treatment, driving innovation and offering renewed hope for improved patient outcomes.

Key Market Players

• Abbott Laboratories Inc.
• Amgen, Inc.
• Celltrion Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Agilent Technologies Inc.
• AstraZeneca Plc
• Pfizer Inc.
• Eli Lilly & Co.
• GlaxoSmithKline Plc.

Report Scope:

In this report, the Global Gastric Cancer Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gastric Cancer Therapy Market, By Therapy Type:

• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Radiation Therapy
• Surgery

Gastric Cancer Therapy Market, By End User:

• Ambulatory Surgery Centers
• Hospitals and Specialty Clinics
• Other

Gastric Cancer Therapy Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gastric Cancer Therapy Market.

Available Customizations:

Global Gastric Cancer Therapy Market report with the given Market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional Market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Gastric Cancer Therapy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy Type (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery)
  • 5.2.2. By End User (Ambulatory Surgery Centers, Hospitals and Specialty Clinics, Other)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Gastric Cancer Therapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy Type
  • 6.2.2. By End User
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Gastric Cancer Therapy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy Type
      • 6.3.1.2.2. By End User
  • 6.3.2. Canada Gastric Cancer Therapy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy Type
      • 6.3.2.2.2. By End User
  • 6.3.3. Mexico Gastric Cancer Therapy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy Type
      • 6.3.3.2.2. By End User

7. Europe Gastric Cancer Therapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy Type
  • 7.2.2. By End User
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Gastric Cancer Therapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy Type
      • 7.3.1.2.2. By End User
  • 7.3.2. United Kingdom Gastric Cancer Therapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy Type
      • 7.3.2.2.2. By End User
  • 7.3.3. Italy Gastric Cancer Therapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy Type
      • 7.3.3.2.2. By End User
  • 7.3.4. France Gastric Cancer Therapy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy Type
      • 7.3.4.2.2. By End User
  • 7.3.5. Spain Gastric Cancer Therapy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy Type
      • 7.3.5.2.2. By End User

8. Asia-Pacific Gastric Cancer Therapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy Type
  • 8.2.2. By End User
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Gastric Cancer Therapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy Type
      • 8.3.1.2.2. By End User
  • 8.3.2. India Gastric Cancer Therapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy Type
      • 8.3.2.2.2. By End User
  • 8.3.3. Japan Gastric Cancer Therapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy Type
      • 8.3.3.2.2. By End User
  • 8.3.4. South Korea Gastric Cancer Therapy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapy Type
      • 8.3.4.2.2. By End User
  • 8.3.5. Australia Gastric Cancer Therapy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapy Type
      • 8.3.5.2.2. By End User

9. South America Gastric Cancer Therapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy Type
  • 9.2.2. By End User
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Gastric Cancer Therapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy Type
      • 9.3.1.2.2. By End User
  • 9.3.2. Argentina Gastric Cancer Therapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy Type
      • 9.3.2.2.2. By End User
  • 9.3.3. Colombia Gastric Cancer Therapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy Type
      • 9.3.3.2.2. By End User

10. Middle East and Africa Gastric Cancer Therapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy Type
  • 10.2.2. By End User
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Gastric Cancer Therapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy Type
      • 10.3.1.2.2. By End User
  • 10.3.2. Saudi Arabia Gastric Cancer Therapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy Type
      • 10.3.2.2.2. By End User
  • 10.3.3. UAE Gastric Cancer Therapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy Type
      • 10.3.3.2.2. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Global Gastric Cancer Therapy Market: SWOT Analysis

16. Competitive Landscape

• 16.1. Abbott Laboratories Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Product & Service Offerings
  • 16.1.3. Recent Developments
  • 16.1.4. Financials (If Listed)
  • 16.1.5. Key Personnel
  • 16.1.6. SWOT Analysis
• 16.2. Amgen, Inc.
• 16.3. Celltrion Inc.
• 16.4. Novartis AG
• 16.5. F. Hoffmann-La Roche Ltd
• 16.6. Agilent Technologies Inc.
• 16.7. AstraZeneca Plc
• 16.8. Pfizer Inc.
• 16.9. Eli Lilly & Co.
• 16.10.GlaxoSmithKline Plc.

17. Strategic Recommendations

18. About Us & Disclaimer